A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects
Condition: Hepatitis C Virus InfectionInterventions: Drug: Daclatasvir; Drug: Asunaprevir; Drug: Ribavirin; Biological: pegIFNα-2b; Drug: TelaprevirSponsor: Bristol-Myers SquibbActive, not recruiting - verified April 2013
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials